1
|
Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Otterbach F, Freudenberg LS. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary:Aims: c-erbB-2 overexpression has been shown to be a potential marker of aggressive biological behaviour in a varity of tumours, whereas its role played in thyroid papillary thyroid carcinoma (PTC) remains unclear. Objective of the study is to determine whether c-erbB-2 overexpression correlates with the clinical course. Methods: We have studied 32 PTC by a two-step immunocytochemical staining procedure for paraffin-embedded specimens (DAKO Hercep- Test). Semiquantitative evaluations were performed, based on the intensity of immunostaining and the percentage of tumor cells. Results: 34% (11/32) of the PTC showed a membranous overexpression of the HER2/neu oncoprotein. Correlating the pathological and clinical data revealed that 81% (9/11) c-erbB-2 positive patients and only 33% (7/21) c-erbB-2 negative patients developed a tumor recurrence or a progression (p = 0.02 in Fisher’s exact test). 3/11 c-erbB-2 positive patients died from PTC whereas all (21/21) c-erbB-2 negative patients are still alive (p=0.03). Conclusions: Our results strongly suggest that c-erbB-2 oncoprotein overexpression is related to the clinical course of PTC.
Collapse
|
2
|
Kern PA, von Minckwitz G, Rietkoetter E, Kimmig R, Rezai M, Otterbach F. Abstract P6-06-23: Glycogen-rich, clear cell breast cancer - An underestimated histopathological risk factor? Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:
Glycogen-rich clear cell carcinoma (GRCCC) is a rare tumour and there is only few data on the prognosis of this subtype, the largest cases series ever published in literature comprising of 21 cases only. (1)
Patients and methods:
In a case-control study of 56 GRCCC early breast cancer cases with matched pairs we analyzed the features of this subtype and survival data regarding DFS and OS.
56 patients with GRCCC have been identified from the period 1992 until 2010 in a multicenter retrospective case cohort trial. To determine the incidence of glycogen-rich clear cell carcinoma in various age groups were stratified in 3 age groups: < 45 years, < 65 years and > 65 years. This was compared to incidence of all breast cancer subtypes due to epidemiological data of Robert-Koch-Institute of the German Ministry of Health.
Results:
Patients were in a range of 33-87 years, median 59,5 years, distributed to the following age groups: 14% (n = 8) of patients were < 45 years, 71,4% (n = 40) < 65 years and 28,6% (n = 16) > 65 years. In the epidemiological data set 10% were < 45 years, 50% < 65 years and 50% > 65 years. Thus patients with glycogen-rich clear cell carcinoma were younger compared to the epidemiological data of all breast cancers registered nationally (< 65 years: 71,4% vs. 50%; p < 0,002).
Stage distribution was as follows: Stage T1 a: no cases, T1b: 2, T1c: 19, T2: 20, T3: 4, T4: 4, unknown T-stage in 7 cases.
Nodal status was in 22 nodal-positive, 23 nodal-negative and 11 with unknown nodal status. The Grading was in G1 none, G2 24 and G3 29 and unknown in 3 cases. Approximated intrinsic tumour subtype was: Luminal A: 10, Luminal B 3, Luminal Her2 positive 16, non-luminal Her2 negative: 14, Triple-Negative Breast Cancer: 7; not further specified: 6.
Chemotherapy was applied in 35 out of 56 patients (62,5%) in our study cohort.
5-years-(OS) was 84% and 5-years (DFS) was 80%. Recurrence rates at a mean time of follow-up of 8,5 years were significantly higher (11 recurrences out of 56 cases) in this specific subtype than in the matched control group (p<0,005).
OS was significantly lower in the group with a local recurrence, dropping down from a 5-years OS-rate of 92% in the recurrence-free group to 48% in the group with a loco-regional recurrence.
Conclusion:
GRCCC of the breast is associated with a highly proliferative and aggressive receptor profile and unfavourable course of disease with significantly higher risk of recurrence (p< 0,005).
This is - to our best knowledge - the largest cohort published in literature on this rare histological subtype of human early breast cancer. Evidence derived from this analysis suggests effective chemotherapy treatment to reduce the risk of recurrence and mortality from this aggressive tumour subtype.
The poor prognosis of 48% in 5-years-overall-survival in case of a loco-regional recurrences of glycogen-rich clear cell carcinom also endorses a role of chemo-therapy in case of recurrence, with regards to the fact that survival rates in this tumor subtype of our cohort were even lower than in the cohort of the CALOR trial.(2)
Literature:
1) Hayes MMM, Am J Surg Pathol. 1995;19:904-911.
2)Aebi S, S3-2. San Antonio Breast Cancer Symposium 2012.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-23.
Collapse
Affiliation(s)
- PA Kern
- University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany
| | - G von Minckwitz
- University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany
| | - E Rietkoetter
- University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany
| | - R Kimmig
- University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany
| | - M Rezai
- University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany
| | - F Otterbach
- University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany
| |
Collapse
|
3
|
Kossakowski CA, Müller KM, Otterbach F. Bronchozentrische Granulomatose in Assoziation mit diffuser neuroendokriner Zellhyperplasie (DIPNECH). Pneumologie 2013. [DOI: 10.1055/s-0033-1334625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
4
|
Riegger C, Koeninger A, Hartung-Knemeyer V, Otterbach F, Kimmig R, Bockisch A, Forsting M, Antoch G, Heusner TA. Vergleich der diagnostischen Genauigkeit der FDG-PET/CT und der Sonographie bei der Detektion axillärer Lymphknotenmetastasen des Mammakarzinoms. ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1311115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
5
|
Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein TC, Antoch G, Heusner TA. Vergleich der diagnostischen Genauigkeit der Ganzkörper- FDG-PET/CT und des konventionellen Algorithmus zum Staging des primären Mammakarzinoms. ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1311318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G, Heusner TA. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 2012; 39:852-63. [PMID: 22392069 DOI: 10.1007/s00259-012-2077-0] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2011] [Accepted: 01/26/2012] [Indexed: 12/13/2022]
Abstract
PURPOSE This retrospective study aimed (1) to compare the diagnostic accuracy of whole-body FDG PET/CT for initial breast cancer staging with the accuracy of a conventional, multimodal imaging algorithm, and (2) to assess potential alteration in patient management based on the FDG PET/CT findings. METHODS Patients with primary breast cancer (106 women, mean age 57 ± 13 years) underwent whole-body FDG PET/CT and conventional imaging (X-ray mammography, MR mammography, chest plain radiography, bone scintigraphy and breast, axillary and liver ultrasonography). The diagnostic accuracies of FDG PET/CT and a conventional algorithm were compared. Diagnostic accuracy was assessed in terms of primary tumour detection rate, correct assessment of primary lesion focality, T stage and the detection rates for lymph node and distant metastases. Histopathology, imaging or clinical follow-up served as the standards of reference. RESULTS FDG PET/CT was significantly more accurate for detecting axillary lymph node and distant metastases (p = 0.0125 and p < 0.005, respectively). No significant differences were detected for other parameters. Synchronous tumours or locoregional extraaxillary lymph node or distant metastases were detected in 14 patients (13%) solely by FDG PET/CT. Management of 15 patients (14%) was altered based on the FDG PET/CT findings, including 3 patients with axillary lymph node metastases, 5 patients with extraaxillary lymph node metastases, 4 patients with distant metastases and 3 patients with synchronous malignancies. CONCLUSION Full-dose, intravenous contrast-enhanced FDG PET/CT was more accurate than conventional imaging for initial breast cancer staging due to the higher detection rate of metastases and synchronous tumours, although the study had several limitations including a retrospective design, a possible selection bias and a relevant false-positive rate for the detection of axillary lymph node metastases. FDG PET/CT resulted in a change of treatment in a substantial proportion of patients.
Collapse
Affiliation(s)
- C Riegger
- Medical Faculty, Department of Diagnostic and Interventional Radiology, Univ Dusseldorf, 40225 Dusseldorf, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Kern P, Kolberg HC, Kalisch A, Liedtke C, Otterbach F, Kimmig R, Kurbacher CM. Pathologic response rate (pCR) and near-pathologic response rate (near-pCR) with docetaxel-carboplatin (TCarb) in early triple-negative breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
277 Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis unless a pathological complete response is achieved (Liedtke C et al. 2008: J Clin Oncol 26:1275-1281) or almost achieved (Symmans WF. 2007: J Clin Oncol 25:4414-4422). Sensitivity to platin compounds has been demonstrated in BRCA1-positive settings (Byrski T et al. 2010: J Clin Oncol 20:28:375-9; Silver DP. 2010: J Clin Oncol 28:1145-1153) with only limited numbers of patients (Byrski T et al. 2010: J Clin Oncol 20:28:375-9) or in sporadic breast cancer with heterogeneous cohorts (Sikov WM et al 2009: J Clin Oncol 27:4693-4700; Chang HR et al. 2010: Cancer 15; 116:4227-4237). Methods: This pivotal trial was to assess the efficacy of platinum and taxane-based combination therapy without the use of anthracyclines. 27 patients with primary TNBC (majority of them cT2, two cT3 and one cT4a) had to be unsuitable for standard anthracycline-based chemotherapy. They received 6 cycles, respectively in two cases only 5 cycles, of carboplatin AUC 6 and docetaxel 75 mg/m2 q3w. The primary endpoint was the pCR-rate, secondary endpoint toxicity. Results: 20 out of 27 (74%) patients had pathological complete response (52%) or near-complete response (22%)—ypT1mic and ypT1a—both being associated with a good prognosis. Seven remaining patients had still good partial response, leaving only low residual cancer burden, which was defined as ypT1. Treatment was well-tolerated: grade III and IV toxicities were neutropenia, thrombopenia, oedema, nausea, joint pain, nail changes, fatigue, hypertension, and alopecia. Conclusions: These results show a high efficacy of carboplatin AUC6 and docetaxel 75 mg/m2 q3w and good feasibility as primary chemotherapy for TNBC with a pCR- and near-pCR-rate of 74% and total response rate of 100%. The incorporation of anthracyclines and parp-inhibitors into further trial designs could enhance the efficacy of these compounds. The omission of exposure to anthracyclines in patients with considerable heart disease risks seems to be feasible with a good pCR-rate, the latter being a surrogate-marker for long-term survival.
Collapse
Affiliation(s)
- P. Kern
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| | - H. C. Kolberg
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| | - A. Kalisch
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| | - C. Liedtke
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| | - F. Otterbach
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| | - R. Kimmig
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| | - C. M. Kurbacher
- University of Duisburg-Essen, Essen, Germany; Marienhospital Bottrop, Bottrop, Germany; West German Study Group and University of Muenster, Muenster, Germany; Institute of Pathology, University of Duisburg-Essen, Essen, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Medical Center Bonn-Friedensplatz, Bonn, Germany
| |
Collapse
|
8
|
Kern P, Otterbach F, Kolberg HC, Pott D, Kalisch A, Kimmig R. Neoadjuvant platin and bevacizumab in triple-negative breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Bornfeld N, Goek M, Akguel H, Zeschnigk M, Otterbach F. Naevus, „indeterminate melanocytic lesion„ oder Melanom? Versuch einer neuen Biopsie-basierten Klassifikation. Klin Monbl Augenheilkd 2010. [DOI: 10.1055/s-0030-1270029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Heusner TA, Hahn S, Jonkmanns C, Kuemmel S, Otterbach F, Hamami ME, Stahl AR, Bockisch A, Forsting M, Antoch G. Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results. Br J Radiol 2010; 84:126-35. [PMID: 20959375 DOI: 10.1259/bjr/93330765] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVES The aim of this study was to evaluate the diagnostic accuracy of fused fluoro-deoxy-D-glucose positron emission tomography/magnetic resonance mammography (FDG-PET/MRM) in breast cancer patients and to compare FDG-PET/MRM with MRM. METHODS 27 breast cancer patients (mean age 58.9±9.9 years) underwent MRM and prone FDG-PET. Images were fused software-based to FDG-PET/MRM images. Histopathology served as the reference standard to define the following parameters for both MRM and FDG-PET/MRM: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for the detection of breast cancer lesions. Furthermore, the number of patients with correctly determined lesion focality was assessed. Differences between both modalities were assessed by McNemaŕs test (p<0.05). The number of patients in whom FDG-PET/MRM would have changed the surgical approach was determined. RESULTS 58 breast lesions were evaluated. The sensitivity, specificity, PPV, NPV and accuracy were 93%, 60%, 87%, 75% and 85% for MRM, respectively. For FDG-PET/MRM they were 88%, 73%, 90%, 69% and 92%, respectively. FDG-PET/MRM was as accurate for lesion detection (p = 1) and determination of the lesions' focality (p = 0.7722) as MRM. In only 1 patient FDG-PET/MRM would have changed the surgical treatment. CONCLUSION FDG-PET/MRM is as accurate as MRM for the evaluation of local breast cancer. FDG-PET/MRM defines the tumours' focality as accurately as MRM and may have an impact on the surgical treatment in only a small portion of patients. Based on these results, FDG-PET/MRM cannot be recommended as an adjunct or alternative to MRM.
Collapse
Affiliation(s)
- T A Heusner
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University at Duisburg-Essen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Affiliation(s)
- E Biewald
- Klinik für Augenheilkunde, Universitätsklinikum Essen.
| | | | | | | |
Collapse
|
12
|
Umutlu L, Heusner TA, Naßenstein K, Koeninger A, Otterbach F, Kimmig R, Stahl A, Antoch G, Lauenstein TC. Neaodjuvante Chemotherapie des Mammakarzinoms: Analyse funktioneller Parameter mit 18 F-FDG-PET/CT und MR Mammographie. ROFO-FORTSCHR RONTG 2010. [DOI: 10.1055/s-0030-1252701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Holdt M, Jurklies C, Schueler A, Otterbach F, Bornfeld N. [Intraocular medulloepithelioma - series of 10 cases and review of the literature]. Klin Monbl Augenheilkd 2009; 226:1017-22. [PMID: 20108196 DOI: 10.1055/s-0028-1109944] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Intraocular medulloepithelioma is an extremely rare unilateral intraocular tumor arising from the nonpigmented ciliary epithelium. Medulloepitheliomas may be classified as benign and malignant and as teratoid and nonteratoid tumors. As a rule a long latency period occurs after first symptoms until the final diagnosis of a medulloepithelioma is made. Differential diagnosis includes in particular unilateral retinoblastoma. Intraocular medulloepithelioma may occur as masquerade-syndrome simulating uveitis. We present 10 patients with intraocular medulloepithelioma. In 7 of these patients the eye had to be enucleated. Metastasis did not occur, but epiretinal tumor seeding did occur in one patient. In one of the 3 not enucleated eyes, ruthenium-106 brachytherapy could salvage the tumor containing eye.
Collapse
Affiliation(s)
- M Holdt
- Zentrum für Augenheilkunde, Universitätsklinikum Essen.
| | | | | | | | | |
Collapse
|
14
|
Otterbach F, Callies R, Kimmig R, Schmid K, Bánkfalvi A. Aquaporin-1-Expression bei invasiven Mammakarzinomen. Pathologe 2008; 29 Suppl 2:357-62. [DOI: 10.1007/s00292-008-1039-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Bachmann HS, Frey UH, Riemann K, Schmitz KJ, Otterbach F, Callies R, Nückel H, Siffert W. The high risk allele of a six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with favorable outcome in multiple cancers. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Hauth EA, Jaeger HJ, Lubnau J, Maderwald S, Otterbach F, Kimmig R, Forsting M. MR-guided vacuum-assisted breast biopsy with a handheld biopsy system: clinical experience and results in postinterventional MR mammography after 24 h. Eur Radiol 2007; 18:168-76. [PMID: 17609959 DOI: 10.1007/s00330-007-0704-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2006] [Revised: 04/27/2007] [Accepted: 06/04/2007] [Indexed: 11/27/2022]
Abstract
This prospective study evaluates the feasibility of the magnetic resonance (MR)-guided vacuum-assisted breast biopsy with a handheld vacuum-biopsy system and documents the biopsy results with MR mammography 24 h after the procedure. MR-guided biopsy was undertaken in 33 patients with 34 lesions on dynamic MR mammography. The interventions were performed with the handheld 10-gauge Vacora vacuum-biopsy system. In all cases, dynamic MR mammography was performed 24 h after the procedure to determine the extent of the lesion removal and to identify the lesions that were missed. In 5/34 (14.7%) lesions, biopsy was not performed because no suspicious lesion was identified on the day of biopsy. In 25/29 (86.2%) lesions, the biopsy was successfully performed with a complete removal in 4/29 (13.8%) and a partial removal of 21/29 (72.4%) lesions. In 4/29 (13.8%) interventions the lesion was missed with the biopsy. In one case, histopathology after surgical excision revealed ductal carcinoma in situ. Histopathology revealed 9/29 (31%) malignant and 20/29 (68.9%) benign lesions. MR-guided vacuum-assisted breast biopsy with the handheld Vacora vacuum-biopsy system is technically feasible in most cases. MR mammography 24 h after the biopsy should be performed in those cases in which the biopsy success is unclear immediately after the procedure.
Collapse
Affiliation(s)
- E A Hauth
- Department of Diagnostic and Interventional, Radiology and Neuroradiology, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany.
| | | | | | | | | | | | | |
Collapse
|
17
|
Oztürk E, Otterbach F, Werner M, Neumann A. [Bone damaging swelling of the side of the nose]. HNO 2007; 54:958-61. [PMID: 16823571 DOI: 10.1007/s00106-006-1443-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- E Oztürk
- Universitäts-Hals-Nasen-Ohren-Klinik, Universitätsklinikum Essen
| | | | | | | |
Collapse
|
18
|
Otterbach F, Schmid KW. [Salivary gland-like tumors of the breast]. Pathologe 2006; 27:363-72. [PMID: 16896677 DOI: 10.1007/s00292-006-0851-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
A subset of rare benign and malignant breast tumors with and without myoepithelial differentiation are morphologically and histogenetically similar to salivary gland tumors, but may differ in incidence and clinical behavior. The clinicopathological, immunohistochemical, molecular and prognostic features of ten salivary gland-like tumor entities of the breast are discussed and compared with their respective counterparts in the salivary glands.
Collapse
Affiliation(s)
- F Otterbach
- Institut für Pathologie und Neuropathologie, Universitätsklinikum, Hufelandstrasse 55, 45122, Essen, Germany.
| | | |
Collapse
|
19
|
Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW, Baba HA. Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol 2006; 59:685-91. [PMID: 16497869 PMCID: PMC1860412 DOI: 10.1136/jcp.2005.030650] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND AND AIM The production of prostaglandins is regulated by cyclo-oxygenases (COXs), which also have a role in tumour development and progression in various malignancies, including breast cancer. The mechanisms by which COX-2 contributes to unfavourable prognosis are still poorly understood. The association between expression of COX-2 and possible linked signalling pathways-namely, Akt, extracellular regulated kinases (ERK1/2), the stress-activated kinase p38 or Her-2/neu-is assessed in a series of 113 node-negative breast cancers. RESULTS COX-2 was identified as an independent prognostic factor (p = 0.034) in node-negative breast cancer by survival analysis. The lack of a relationship between COX-2 expression and activated Akt, Erk1/2, p38 and Her-2/neu was indicated by statistical analysis. CONCLUSIONS The prognostic effect of COX-2 expression on lymph node-negative breast cancer is confirmed-COX-2 is probably not regulated by HER-2, Akt, Erk1/2 or p38. Further studies are necessary for the elucidation of the signalling pathways responsible for the modification of COX-2 expression and the increased aggressiveness of breast cancers overexpressing COX-2.
Collapse
Affiliation(s)
- K J Schmitz
- Institute of Pathology, University Hospital of Essen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Hauth EA, Reiter K, Hoffmann O, Otterbach F, Kimmig R, Forsting M. Die Magnetresonanztomographie(MRT)-gesteuerte Mamma-Vakuumbiopsie mit dem Vacora®-System. ACTA ACUST UNITED AC 2005; 127:400-6. [PMID: 16341985 DOI: 10.1055/s-2005-836907] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE This prospective study was undertaken to determine the feasibility of MR-guided vacuum assisted breast biopsy with the Vacora-vacuum-biopsy system for histological evaluation of suspicious lesions in MR-mammography. MATERIAL AND METHODS During 3 months MR-guided vacuum assisted breast biopsy was indicated in 12 patients with suspicious lesions in MR-mammography. RESULTS MR-guided vacuum assisted breast biopsy with the Vacora-vacuum-biopsy system could be performed in 9 of 12 patients. In 2 patients the lesions could not be identified at the time of the intervention. In one patient the intervention could not be performed due to obesity. Histopathology revealed benign lesions in 8 patients and malignancy in one patient. In one of the cases with benign histology, the biopsy specimen was not representative for the lesion. CONCLUSIONS MR-guided vacuum assisted breast biopsy with Vacora-vacuum-biopsy is technical feasible can be performed with a low complication rate.
Collapse
Affiliation(s)
- E A Hauth
- Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen.
| | | | | | | | | | | |
Collapse
|
21
|
Schmitz KJ, Grabellus F, Callies R, Wohlschlaeger J, Otterbach F, Kimmig R, Levkau B, Schmid KW, Baba HA. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression. Virchows Arch 2005; 448:16-23. [PMID: 16208531 DOI: 10.1007/s00428-005-0086-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2005] [Accepted: 09/01/2005] [Indexed: 12/15/2022]
Abstract
The Akt signalling pathway plays a central role in tumourigenesis. Activation of Akt is related to a more aggressive phenotype in various human cancers, including breast cancer. Its activation contributes to cancer progression via pleiotropic effects, including suppression of apoptosis and modulation of cell cycle regulation. Murine double minute 2 (MDM2) is an oncoprotein that inhibits the function of p53 tumour suppressor protein. Cell culture studies show that Akt-related phosphorylation of MDM2 at serine 166 allows MDM2 to gain nuclear entry and fulfil its p53 regulating function. This study was designed to analyse the relationship of phospho-MDM2 (pMDM2) expression with Akt activation to determine a possible prognostic relevance of pMDM2 in node-negative breast cancer with respect to Akt activation and p53 status. pMDM2, phospho-Akt (pAkt) and p53 protein expression status were analysed immunohistochemically in 121 paraffin-embedded breast cancer cases. Expression of pMDM2 correlated with Akt activation (P<0.001). Univariate analysis identified pMDM2 as a prognostic factor (P=0.0458) in node-negative breast cancers. The unfavourable prognostic significance was even more pronounced in tumours with a pMDM2(+)/pAkt(+) immunophenotype (P=0.0205). Stratification into a p53-negative subgroup further strengthened the adverse prognostic influence. These data confirm that MDM2 phosphorylation at serine 166 is mediated by Akt kinase. Besides the prognostic impact of pMDM2, our findings suggest that Akt-mediated modulation of the MDM2/p53 complex contributes to increased tumour aggressiveness especially in p53-negative breast cancers. However, due to the relatively small number of patients in this cohort, the results obtained need to be confirmed by larger cohorts.
Collapse
Affiliation(s)
- K J Schmitz
- Institute of Pathology, Hufelandstr. 55, 45122 Essen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Grabellus F, Worm K, Willruth A, Schmitz KJ, Otterbach F, Baba HA, Kimmig R, Metz KA. ETV6–NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast 2005; 14:71-4. [PMID: 15695086 DOI: 10.1016/j.breast.2004.04.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2004] [Revised: 03/25/2004] [Accepted: 04/15/2004] [Indexed: 10/26/2022] Open
Abstract
Secretory carcinomas of the breast were first described as "juvenile carcinoma" by McDivitt and Stewart in a cohort of children. This term has been replaced by the term "secretory breast carcinoma", because the entity can occur at any time of life. Carcinoma of the male breast is uncommon and accounts for approximately 1% of all cancers in men. Recently, it has been reported that human secretory breast carcinoma expresses the ETV6-NTRK3 gene fusion that was previously cloned in pediatric mesenchymal cancers. We present the case of a 46-year-old male-to-female transsexual in whom a secretory breast carcinoma was an incidental finding. As confirmation of the histopathological diagnosis we detected the novel ETV6-NTRK3 gene fusion in this tumor.
Collapse
Affiliation(s)
- F Grabellus
- Institute of Pathology, University Hospital of Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Bockisch A, Otterbach F. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 2005; 44:179-82, 184. [PMID: 16395492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
AIMS c-erbB-2 overexpression has been shown to be a potential marker of aggressive biological behaviour in a varity of tumours, whereas its role played in thyroid papillary thyroid carcinoma (PTC) remains unclear. Objective of the study is to determine whether c-erbB-2 overexpression correlates with the clinical course. METHODS We have studied 32 PTC by a two-step immunocytochemical staining procedure for paraffin-embedded specimens (DAKO Hercep-Test). Semiquantitative evaluations were performed, based on the intensity of immunostaining and the percentage of tumor cells. RESULTS 34% (11/32) of the PTC showed a membranous overexpression of the HER2/neu oncoprotein. Correlating the pathological and clinical data revealed that 81% (9/11) c-erbB-2 positive patients and only 33% (7/21) c-erbB-2 negative patients developed a tumor recurrence or a progression (p = 0.02 in Fisher's exact test). 3/11 c-erbB-2 positive patients died from PTC whereas all (21/21) c-erbB-2 negative patients are still alive (p = 0.03). CONCLUSIONS Our results strongly suggest that c-erbB-2 oncoprotein overexpression is related to the clinical course of PTC.
Collapse
Affiliation(s)
- L S Freudenberg
- Department of Nuclear Medicine, University of Essen, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Sheu SY, Wenzel RR, Kersting C, Merten R, Otterbach F, Schmid KW. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol 2004; 57:1225-8. [PMID: 15509691 PMCID: PMC1770491 DOI: 10.1136/jcp.2004.018481] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Erdheim-Chester disease is a rare non-Langerhans' cell histiocytosis with characteristic radiological and histological features. This entity is defined by a mononuclear infiltrate consisting of lipid laden, foamy histiocytes that stain positively for CD68. About half of those affected have extraskeletal manifestations, including involvement of the hypothalamus-pituitary axis, lung, heart, retroperitoneum, skin, liver, kidneys, spleen, and orbit. This report describes the case of a 50 year old white man who presented with hypogonadism and diabetes insipidus. At necropsy, extensive organ involvement was found, including the testes, thyroid, and lymph nodes. This is the first report of thyroid and lymph node infiltration in this disease. Because of the endocrinological symptoms, neurosarcoidosis and hypophysitis are important diseases in the differential diagnosis. This report also includes a review of the literature concerning rare organ manifestations and patients presenting primarily with similar symptoms.
Collapse
Affiliation(s)
- S-Y Sheu
- Institute of Pathology, University of Essen, 45122 Essen, Germany.
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
Hyperparathyroidism is mainly caused by hyperplasia or adenomas of the parathyroid glands. Formerly, the therapeutic strategy depended on the morphological diagnosis (preferentially already made intraoperatively by examination of frozen sections). Today, however, the extent of parathyroid surgery is in many cases guided both by substantial improvements in the preoperative clinical diagnosis as well as the intraoperatively determined decrease in the serum parathyroid hormone level. Nevertheless, the pathologist should be familiar with the differential diagnostic criteria of parathyroid hyperplasia, adenoma, and carcinoma.
Collapse
Affiliation(s)
- S-Y Sheu
- Institut für Pathologie, Universitätsklinikum Essen, Germany
| | | | | | | |
Collapse
|
26
|
Hengge UR, Jochum C, Tschakarjan E, Maschke J, Erbel R, Schmid KW, Otterbach F. [Purpura fulminans. A fatal consequence of a widely used medication?]. Hautarzt 2002; 53:483-7. [PMID: 12219272 DOI: 10.1007/s00105-002-0346-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A 39-year old man developed purpura fulminans, a manifestation of disseminated intravascular coagulopathy, with rhabdomyolsis following the i.m. injection of diclofenac.
Collapse
Affiliation(s)
- U R Hengge
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Germany.
| | | | | | | | | | | | | |
Collapse
|
27
|
Otterbach F, Bànkfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000; 37:232-40. [PMID: 10971699 DOI: 10.1046/j.1365-2559.2000.00882.x] [Citation(s) in RCA: 139] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS This study was performed to determine the diagnostic value of keratin 5/6 (CK 5/6) immunophenotyping on routinely processed breast tissues. METHODS AND RESULTS Six hundred and ninety-nine breast lesions, including normal tissues as well as benign and malignant lesions in 321 formalin-fixed, paraffin-embedded samples from 158 different patients were investigated immunohistochemically, following wet autoclave pre-treatment for antigen retrieval. In normal breast tissues, both myoepithelial and luminal epithelial cells expressed CK 5/6 in varying amounts. While myoepithelial immunoreactivity was most pronounced in the duct system, luminal epithelial immunoreactivity was strongest in the terminal duct lobular units. In ductal hyperplasias (DH), luminal epithelial cells predominantly revealed CK 5/6 immunoreaction. In contrast, neoplastic epithelial cells in atypical ductal and lobular hyperplasias (ADH and ALH) lacked such an expression, whereas in ductal in-situ carcinomas (DCIS) and in infiltrating ductal carcinomas 3.7% and 7.7%, of the cases respectively, showed positive immunostaining for CK 5/6. CONCLUSIONS Immunophenotyping of keratin 5/6 expression can be helpful in the diagnosis of atypical hyperplasias and in-situ carcinomas of the breast. It is particularly valuable in the differential diagnosis between benign and atypical proliferative lesions.
Collapse
Affiliation(s)
- F Otterbach
- Gerhard-Domagk-Institute of Pathology, University of Münster, Department of Pathology, City Hospital, Osnabrück, and City Hospital, Berlin-Buch, Germany
| | | | | | | | | | | |
Collapse
|
28
|
Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 2000. [PMID: 10629552 DOI: 10.1002/(sici)1096-9896(199912)189:4<521::aid-path472>3.0.co;2-b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Invasive breast cancer shows a wide range of morphological differentiation, associated with differences in prognosis, but as yet, the underlying genetic mechanisms cannot be accounted for. In order to establish a model of the possible progression from the different subtypes of ductal carcinoma in situ (DCIS) to invasive breast cancer, 77 selected cases of invasive breast cancer representing distinct morphological subtypes were investigated by means of comparative genomic hybridization (CGH). There was a high degree of genetic homology between tubular and tubulo-lobular carcinoma and well-differentiated DCIS, and between ductal invasive carcinoma G3 and poorly differentiated DCIS. Highly differentiated invasive breast cancers were characterized by a loss of 16q and a low average number of aberrations per case. In high-grade tumours, losses of this chromosomal region were seen with a much lower frequency in cases with evidence of an aneuploid tumour status. These data demonstrate the close genetic similarity of well-, intermediately, and poorly differentiated DCIS and distinct morphological types of invasive breast carcinoma, providing further evidence that DCIS is a direct precursor lesion of invasive breast cancer and that various evolutionary genetic pathways exist.
Collapse
Affiliation(s)
- H Buerger
- Gerhard-Domagk-Institute of Pathology, University of Münster, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999; 189:521-6. [PMID: 10629552 DOI: 10.1002/(sici)1096-9896(199912)189:4<521::aid-path472>3.0.co;2-b] [Citation(s) in RCA: 195] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Invasive breast cancer shows a wide range of morphological differentiation, associated with differences in prognosis, but as yet, the underlying genetic mechanisms cannot be accounted for. In order to establish a model of the possible progression from the different subtypes of ductal carcinoma in situ (DCIS) to invasive breast cancer, 77 selected cases of invasive breast cancer representing distinct morphological subtypes were investigated by means of comparative genomic hybridization (CGH). There was a high degree of genetic homology between tubular and tubulo-lobular carcinoma and well-differentiated DCIS, and between ductal invasive carcinoma G3 and poorly differentiated DCIS. Highly differentiated invasive breast cancers were characterized by a loss of 16q and a low average number of aberrations per case. In high-grade tumours, losses of this chromosomal region were seen with a much lower frequency in cases with evidence of an aneuploid tumour status. These data demonstrate the close genetic similarity of well-, intermediately, and poorly differentiated DCIS and distinct morphological types of invasive breast carcinoma, providing further evidence that DCIS is a direct precursor lesion of invasive breast cancer and that various evolutionary genetic pathways exist.
Collapse
MESH Headings
- Adenocarcinoma/chemistry
- Adenocarcinoma/genetics
- Adenocarcinoma/pathology
- Adenocarcinoma, Mucinous/chemistry
- Adenocarcinoma, Mucinous/genetics
- Adenocarcinoma, Mucinous/pathology
- Breast Neoplasms/chemistry
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/chemistry
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/pathology
- Chromosome Aberrations
- Female
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
Collapse
Affiliation(s)
- H Buerger
- Gerhard-Domagk-Institute of Pathology, University of Münster, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 1999. [PMID: 10398097 DOI: 10.1002/(sici)1096-9896(199903)187:4<396::aid-path286>3.0.co;2-l] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
There is strong evidence that ductal carcinoma in situ (DCIS) represents a precursor lesion of invasive breast cancer. In order to analyse specific chromosomal alterations of DCIS, 38 paraffin-embedded specimens of DCIS and six associated invasive carcinomas were examined by means of comparative genomic hybridization (CGH). Losses of 16q material were seen almost exclusively in well- and intermediately-differentiated DCIS. These two subgroups differed in the average number of genetic imbalances, 2.5 and 5.5 respectively. Additionally, a higher frequency of gains of 1q and losses of 11q material was seen in intermediately-differentiated in contrast to well-differentiated DCIS. Poorly-differentiated DCIS displayed a higher frequency of amplifications (17q12, 11q13) and a higher average rate of genetic imbalances (7.1). Analysis of adjacent invasive breast carcinoma revealed a genetic pattern almost identical to the one seen in the DCIS counterpart. These data characterize DCIS as a genetically far-advanced, heterogeneous lesion and as a direct precursor of invasive breast cancer.
Collapse
Affiliation(s)
- H Buerger
- Gerhard-Domagk-Institute of Pathology, University of Münster, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 1999; 187:396-402. [PMID: 10398097 DOI: 10.1002/(sici)1096-9896(199903)187:4<396::aid-path286>3.0.co;2-l] [Citation(s) in RCA: 270] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
There is strong evidence that ductal carcinoma in situ (DCIS) represents a precursor lesion of invasive breast cancer. In order to analyse specific chromosomal alterations of DCIS, 38 paraffin-embedded specimens of DCIS and six associated invasive carcinomas were examined by means of comparative genomic hybridization (CGH). Losses of 16q material were seen almost exclusively in well- and intermediately-differentiated DCIS. These two subgroups differed in the average number of genetic imbalances, 2.5 and 5.5 respectively. Additionally, a higher frequency of gains of 1q and losses of 11q material was seen in intermediately-differentiated in contrast to well-differentiated DCIS. Poorly-differentiated DCIS displayed a higher frequency of amplifications (17q12, 11q13) and a higher average rate of genetic imbalances (7.1). Analysis of adjacent invasive breast carcinoma revealed a genetic pattern almost identical to the one seen in the DCIS counterpart. These data characterize DCIS as a genetically far-advanced, heterogeneous lesion and as a direct precursor of invasive breast cancer.
Collapse
Affiliation(s)
- H Buerger
- Gerhard-Domagk-Institute of Pathology, University of Münster, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Poremba C, Böcker W, Willenbring H, Schäfer KL, Otterbach F, Bürger H, Diallo R, Dockhorn-Dworniczak B. Telomerase activity in human proliferative breast lesions. Int J Oncol 1998; 12:641-8. [PMID: 9472105 DOI: 10.3892/ijo.12.3.641] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Telomerase, a cellular reverse transcriptase, has been detected in the majority of human malignant tumors, where it provides an escape mechanism from proliferative limitations due to progressive telomere erosion with each cell division. In this study, we used a non-radioactive telomeric repeat amplification protocol (TRAP) with an internal telomerase assay standard for the detection and semiquantitative analysis of 98 single frozen sections of normal breast tissue and benign and malignant breast lesions on an automated laser-fluorescence sequencer. Telomerase activity was detected in 36 of 40 (90%) infiltrating breast carcinomas, whereas no activity was found in nonmalignant breast tissues including blunt duct adenosis, papilloma, ductal hyperplasia and atypical ductal hyperplasia. However, telomerase activity was detected in 59% of ductal in situ carcinomas, suggesting that telomerase reactivation is an early event in breast carcinogenesis. We found a positive correlation between telomerase activity levels and cell proliferation determined by MIB1 immunostaining. No correlation, however, could be demonstrated between telomerase activity and other known breast cancer prognostic indicators. Telomerase activity was also detected in 60% of fibroadenomas indicating that careful interpretation of analysis of telomerase activity in fine needle aspirates is required, since low telomerase activity may not necessarily be an indicator of malignancy in breast tissue.
Collapse
Affiliation(s)
- C Poremba
- Gerhard-Domagk-Institute of Pathology, Domagkstrasse 17, University of Munster, D-48149 Munster, Germany
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Hettlich HJ, Otterbach F, Mittermayer C, Kaufmann R, Klee D. Plasma-induced surface modifications on silicone intraocular lenses: chemical analysis and in vitro characterization. Biomaterials 1991; 12:521-4. [PMID: 1892989 DOI: 10.1016/0142-9612(91)90153-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In contrast to the high standard of intraocular lens implantation today, lens fixation and the occurrence of secondary opacifications are still not satisfactory. We are working on an implant that builds a stable connection to the surrounding lens-capsule. Disc-shaped lenses made of poly(dimethylsiloxane) were treated with different kinds of plasma to bring functional groups to the surface. This allows further macromolecular coating. The results of the surface modifications were characterized by electron spectroscopy for chemical analysis, scanning electron microscopy, Fourier transform infrared spectroscopy and cell culture experiments. O2 plasma induces a rapid increase of functional groups on the lens surface. CO2 plasma has to be used for longer treatment periods to achieve the same increase, but as SEM shows, did not lead to surface damage up to periods of 300 s. Using O2 plasma for longer than 60 s, a crack formation occurred. Therefore, CO2 plasma may be a more effective and sensitive tool in grafting functional groups to the surface.
Collapse
|